London

Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are…

Polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors

London

Roots Analysis has announced the addition of “Polycystic Ovary Syndrome Market, 2021-2031” report to its list of offerings.

Currently, there is no cure for polycystic ovary syndrome (PCOS / PCOD), however the affiliated symptoms can be treated using a…

Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Repurposing Service Providers Market, 2020-2030.”

The report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. It features an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. In addition to other elements, the study…

A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios and utilize diverse patient outreach methods to recruit study participants across different…